Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4- (N)-Docosahexaenoyl 2' ,2 '-

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer.

  2015cited by this paper
• The targeting mechanism of DHA ligand and its conjugate with Gemcitabine for the enhanced tumor therapy

  2014cited by this paper
• New Treatments for Bladder Cancer: When Will We Make Progress?

  2014cited by this paper
• Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and in Vivo Evaluation

  2014cited by this paper
• Therapeutic Modalities of Squalenoyl Nanocomposites in Colon Cancer: An Ongoing Search for Improved Efficacy

  2014cited by this paper
• Enhanced Tumor Delivery of Gemcitabine via PEG-DSPE/TPGS Mixed Micelles

  2014cited by this paper
• Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.

  2014cited by this paper
• Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.

  2014cited by this paper
• Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer

  2014cited by this paper
• Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.

  2013cited by this paper
• Recent progress in pancreatic cancer

  2013cited by this paper
• Dietary Energy Balance Modulation of Kras- and Ink4a/Arf+/−-Driven Pancreatic Cancer: The Role of Insulin-like Growth Factor-I

  2013cited by this paper
• The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.

  2013cited by this paper
• EPA, an omega‐3 fatty acid, induces apoptosis in human pancreatic cancer cells: Role of ROS accumulation, caspase‐8 activation, and autophagy induction

  2013cited by this paper
• Inhibition of matrix metalloproteinase-9 expression by docosahexaenoic acid mediated by heme oxygenase 1 in 12-O-tetradecanoylphorbol-13-acetate-induced MCF-7 human breast cancer cells

  2013cited by this paper
• Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.

  2013cited by this paper
• Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.

  2013cited by this paper
• Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model

  2013cited by this paper
• Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil.

  2013cited by this paper
• Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis

  2013cited by this paper
• DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA

  2013cited by this paper
• Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.

  2013cited by this paper
• Stability of caffeic acid phenethyl amide (CAPA) in rat plasma.

  2012cited by this paper
• EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.

  2012cited by this paper
• Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.

  2012cited by this paper
• Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.

  2012cited by this paper
• Docosahexaenoic acid inhibits invasion of human RT112 urinary bladder and PT45 pancreatic carcinoma cells via down-modulation of granzyme B expression.

  2012cited by this paper
• Only women with symptoms need to have their breast implants removed, says government

  2012cited by this paper
• Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo.

  2012cited by this paper
• In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.

  2011cited by this paper
• Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.

  2011cited by this paper
• Supplementation with fish oil increases first‐line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer

  2011cited by this paper
• The ARF Tumor Suppressor Inhibits Tumor Cell Colonization Independent of p53 in a Novel Mouse Model of Pancreatic Ductal Adenocarcinoma Metastasis

  2011cited by this paper
• A high omega-3 fatty acid diet mitigates murine pancreatic precancer development.

  2011cited by this paper
• Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.

  2011cited by this paper
• Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.

  2011cited by this paper
• PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

  2010cited by this paper
• Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer.

  2010cited by this paper
• Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma

  2010cited by this paper
• Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.

  2009cited by this paper
• Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions

  2009cited by this paper
• The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential.

  2009cited by this paper
• Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.

  2008cited by this paper
• Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms

  2008cited by this paper
• Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine Anticancer Nanomedicine

  2008cited by this paper
• Pancreatic cancer: progress in cancer therapy.

  2008cited by this paper
• Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC.

  2007cited by this paper
• A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.

  2007cited by this paper
• Docosahexaenoic Acid (DHA), a Primary Tumor Suppressive Omega-3 Fatty Acid, Inhibits Growth of Colorectal Cancer Independent of p53 Mutational Status

  2007cited by this paper
• Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate.

  2006cited by this paper
• Squalenoyl nanomedicines as potential therapeutics.

  2006cited by this paper
• Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate.

  2005cited by this paper
• Docosahexaenoic Acid Induces Apoptosis in the Human PaCa-44 Pancreatic Cancer Cell Line by Active Reduced Glutathione Extrusion and Lipid Peroxidation

  2005cited by this paper
• Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002).

  2005cited by this paper
• A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms

  2005cited by this paper
• Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.

  2004cited by this paper
• RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

  2004cited by this paper
• Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs.

  2004cited by this paper
• Chemical Stability of Esters of Nicotinic Acid Intended for Pulmonary Administration by Liquid Ventilation

  2003cited by this paper
• Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

  2003cited by this paper
• Induction of Apoptosis in Human Pancreatic Cancer Cells by Docosahexaenoic Acid

  2003cited by this paper
• Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)

  2002cited by this paper
• Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model

  2001cited by this paper
• Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.

  2001cited by this paper
• Tumor targeting by conjugation of DHA to paclitaxel.

  2001cited by this paper
• Selective Protection of 2',2'-Difluorodeoxycytidine (Gemcitabine).

  1999cited by this paper
• In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

  1999cited by this paper
• Gemcitabine: a cytidine analogue active against solid tumors.

  1997cited by this paper
• The estimation of relative water solubility for prodrugs that are unstable in water

  1993cited by this paper
• A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

  1991cited by this paper

• No citing papers are available for this paper.